Nevertheless, based on compelling preclinical evidence, the ERK1/2 pathway is being explored both for its prognostic value [28] and as a new potential therapeutic approach in iCCA management [27]. This evidence concerns the gene MAPK3 and infantile convulsions and choreoathetosis.